PriceTargets.com logo

ZyVersa Therapeutics - ZVSA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $120.00
  • Forecasted Upside: 5,404.59%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.18 As of 09/13/2024 09:54 PM ET
▼ -0.05 (-2.24%)

This chart shows the closing price for ZVSA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ZyVersa Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZVSA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZVSA

Analyst Price Target is $120.00
▲ +5,404.59% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for ZyVersa Therapeutics in the last 3 months. The average price target is $120.00, with a high forecast of $120.00 and a low forecast of $120.00. The average price target represents a 5,404.59% upside from the last price of $2.18.

This chart shows the closing price for ZVSA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in ZyVersa Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$120.00Low
2/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$240.00Low
9/8/2023HC WainwrightInitiated CoverageBuy$875.00Low
(Data available from 9/16/2019 forward)

News Sentiment Rating

1.11 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
2/19/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

ZyVersa Therapeutics logo
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.
Read More

Today's Range

Now: $2.18
Low: $2.14
High: $2.39

50 Day Range

MA: $3.37
Low: $2.18
High: $6.18

52 Week Range

Now: $2.18
Low: $2.08
High: $62.30

Volume

229,100 shs

Average Volume

219,603 shs

Market Capitalization

$1.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Frequently Asked Questions

What sell-side analysts currently cover shares of ZyVersa Therapeutics?

The following Wall Street analysts have issued stock ratings on ZyVersa Therapeutics in the last twelve months: HC Wainwright.
View the latest analyst ratings for ZVSA.

What is the current price target for ZyVersa Therapeutics?

1 Wall Street analysts have set twelve-month price targets for ZyVersa Therapeutics in the last year. Their average twelve-month price target is $120.00, suggesting a possible upside of 5,404.6%. HC Wainwright has the highest price target set, predicting ZVSA will reach $120.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $120.00 for ZyVersa Therapeutics in the next year.
View the latest price targets for ZVSA.

What is the current consensus analyst rating for ZyVersa Therapeutics?

ZyVersa Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZVSA will outperform the market and that investors should add to their positions of ZyVersa Therapeutics.
View the latest ratings for ZVSA.

What other companies compete with ZyVersa Therapeutics?

Other companies that are similar to ZyVersa Therapeutics include PHAXIAM Therapeutics, Mustang Bio, Kiora Pharmaceuticals, Agile Therapeutics and Jaguar Health. Learn More about companies similar to ZyVersa Therapeutics.

How do I contact ZyVersa Therapeutics' investor relations team?

ZyVersa Therapeutics' physical mailing address is 100 Somerset Corporate Blvd. 2nd Floor, Bridgewater NJ, 08807. The company's listed phone number is 754-231-1688 and its investor relations email address is [email protected]. The official website for ZyVersa Therapeutics is www.zyversa.com. Learn More about contacing ZyVersa Therapeutics investor relations.